Atara Biotherapeutics (ATRA) Current Deferred Revenue (2020 - 2026)

Atara Biotherapeutics' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $684000.0 for Q1 2026.

• Quarterly Current Deferred Revenue fell 95.72% year-over-year to $684000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $684000.0 (down 95.72% YoY) and the FY2025 annual result came in at $716000.0, down 99.25% from the prior year.
• Current Deferred Revenue was $684000.0 for Q1 2026 at Atara Biotherapeutics, down from $716000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $123.2 million in Q1 2024 and bottomed at $684000.0 in Q1 2026.
• A 5-year average of $37.5 million and a median of $11.6 million in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 1140.97% — and 2025, when it slumped 99.25%.
• Atara Biotherapeutics' Current Deferred Revenue stood at $8.0 million in 2022, then soared by 872.91% to $77.8 million in 2023, then gained by 22.17% to $95.1 million in 2024, then slumped by 99.25% to $716000.0 in 2025, then retreated by 4.47% to $684000.0 in 2026.
• Business Quant data shows ATRA's Current Deferred Revenue at $684000.0 in Q1 2026, $716000.0 in Q4 2025, and $1.0 million in Q3 2025.